Upgrade to SI Premium - Free Trial

VistaGen Therapeutics (VTGN)

0.59 +0.02 (3.51%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/13/26 *Est.)

Latest Headlines

Form 8-K Vistagen Therapeutics, For: Jun 09 June 9, 2026 5:05 PM - SEC Filing Vistagen meets ICH safety exposure standards for fasedienol trials June 9, 2026 8:31 AM - StreetInsider Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder June 9, 2026 8:30 AM - BizWire Vistagen to Participate in Jefferies 2026 Global Healthcare Conference May 27, 2026 8:30 AM - BizWire Form 4 Vistagen Therapeutics, For: May 18 Filed by: Angelov Angel S May 19, 2026 4:52 PM - SEC Filing Form 3 Vistagen Therapeutics, For: May 18 Filed by: Angelov Angel S May 19, 2026 4:52 PM - SEC Filing Form 8-K Vistagen Therapeutics, For: May 18 May 19, 2026 4:30 PM - SEC Filing Vistagen names Angel Angelov as chief medical officer May 19, 2026 8:30 AM - StreetInsider Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer May 19, 2026 8:30 AM - BizWire Form SCHEDULE 13G/A Vistagen Therapeutics, Filed by: TCG Crossover GP II, LLC May 15, 2026 4:33 PM - SEC Filing Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference May 14, 2026 8:30 AM - BizWire Form 8-K Vistagen Therapeutics, For: May 12 May 12, 2026 7:45 AM - SEC Filing Vistagen reports preliminary positive safety data from fasedienol trial May 12, 2026 7:30 AM - StreetInsider Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder May 12, 2026 7:30 AM - BizWire Form 8-K Vistagen Therapeutics, For: May 08 May 8, 2026 4:30 PM - SEC Filing VistaGen completes PALISADE-4 phase 3 study of fasedienol for social anxiety May 8, 2026 7:30 AM - StreetInsider Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder May 8, 2026 7:30 AM - BizWire Form 8-K Vistagen Therapeutics, For: Apr 22 April 28, 2026 4:14 PM - SEC Filing Vistagen gets FDA clearance for refisolone menopause trial April 22, 2026 8:30 AM - StreetInsider Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Me April 22, 2026 8:30 AM - BizWire Form 8-K Vistagen Therapeutics, For: Apr 07 April 13, 2026 5:28 PM - SEC Filing Form 4 Vistagen Therapeutics, For: Apr 07 Filed by: Tressler Nick B. April 9, 2026 8:43 PM - SEC Filing Form 4 Vistagen Therapeutics, For: Apr 07 Filed by: Singh Shawn April 9, 2026 8:42 PM - SEC Filing Form 4 Vistagen Therapeutics, For: Apr 07 Filed by: Prince Joshua S. April 9, 2026 8:40 PM - SEC Filing Form 4 Vistagen Therapeutics, For: Apr 07 Filed by: Cote Elissa S. April 9, 2026 8:39 PM - SEC Filing Form 4 Vistagen Therapeutics, For: Apr 07 Filed by: Adler Reid G. April 9, 2026 8:33 PM - SEC Filing Form 8-K Vistagen Therapeutics, For: Apr 01 April 2, 2026 4:17 PM - SEC Filing Form 8-K Vistagen Therapeutics, For: Mar 17 March 18, 2026 4:46 PM - SEC Filing Form 8-K Vistagen Therapeutics, For: Mar 16 March 16, 2026 4:11 PM - SEC Filing Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN March 16, 2026 2:38 AM - PR NewsWire Full Article List